Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis

Abstract Background & Aims Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous neoplasms. Although some have a relatively benign and indolent natural history, others can be aggressive and ultimately fatal. Somatostatin analogues (SSAs) improve both quality of life and survi...

Full description

Bibliographic Details
Main Authors: Sheila D. Rustgi, Aaron Oh, Jeong Yun Yang, Dasol Kang, Edward Wolin, Chung Y. Kong, Chin Hur, Michelle K. Kim
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Cancer
Subjects:
Neuroendocrine tumors
Cost-effectiveness analysis
Somatostatin analogues
Carcinoid
Peptide receptor radionuclide therapy
Online Access:https://doi.org/10.1186/s12885-021-08306-5

Internet

https://doi.org/10.1186/s12885-021-08306-5

Similar Items